[1]张文静a,郑维威a,宋闿迪b,等.慢性粒细胞白血病患者骨髓单个核细胞中CaMKⅡγ在疾病不同阶段的表达及分子机制[J].现代检验医学杂志,2018,33(03):8-10.[doi:10.3969/j.issn.1671-7414.2018.03.003]
　ZHANG Wen-jinga,ZHENG Wei-weia,SONG Kai-dib,et al.Expression and Molecular Mechanism of CaMK II Gamma of Bone Marrow Mononuclear Cells in Different Stages of Patients with CML[J].Journal of Modern Laboratory Medicine,2018,33(03):8-10.[doi:10.3969/j.issn.1671-7414.2018.03.003]
点击复制

慢性粒细胞白血病患者骨髓单个核细胞中CaMKⅡγ在疾病不同阶段的表达及分子机制()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年03期
页码:
8-10
栏目:
论著
出版日期:
2018-07-17

文章信息/Info

Title:
Expression and Molecular Mechanism of CaMK II Gamma of Bone Marrow Mononuclear Cells in Different Stages of Patients with CML
文章编号:
1671-7414(2018)03-008-03
作者:
张文静1a; 郑维威1a; 宋闿迪1b; 朱俊锋2; 王保龙1a
1.安徽医科大学附属省立医院a.检验科; b.血液科, 合肥 230000; 2.蚌埠医学院第一附属医院血液科,安徽蚌埠 233000
Author(s):
ZHANG Wen-jing1a; ZHENG Wei-wei1a; SONG Kai-di1b; ZHU Jun-feng2; WANG Bao-long1a
1a.Department of Clinical Laboratory; 1b.Department ofHematology,Affiliated Provincial Hospital of Anhui Medical University,Hefei 230000,China; 2.Department of Hematology, the First Affiliated Hospital of Bengbu Medical College,Anhui Bengbu 233000,China
关键词:
慢性粒细胞白血病;  CaMKⅡγ;  分子机制
分类号:
R557.3
DOI:
10.3969/j.issn.1671-7414.2018.03.003
文献标志码:
A
摘要:
目的 探讨钙调蛋白依赖性激酶Ⅱγ(CaMKⅡγ)在慢性粒细胞白血病患者从慢性期到急变期过渡的表达及其分子机制。方法 59例来自不同时期慢性粒细胞白血病患者的骨髓,通过Ficoll分离液分离单个核细胞,裂解蛋白进行Western blot检测CaMKⅡγ的表达,并初步探讨其分子机制。结果 CaMKⅡγ在慢粒加速和急变期患者中高表达,而慢性期患者表达量低或不表达,其表达与β-catenin基本一致。结论 CaMKⅡγ在慢性粒细胞白血病慢性期到加速期过渡中发挥重要作用,可通过调控β-catenin的表达影响白血病干细胞的自我更新。
Abstract:
Abstract:Objective To investigate the expression and molecular mechanism of CaMK II gamma in CML patients transitted from chronic phaseto acute phase.Methods 59 cases of bone marrow from CMLpatients in different periods were chosed.The mononuclear cells were separatedby Ficoll separation,the protein expression of CaMK II gamma was detected by Western blot,and explored its molecular mechanism.Results The expression of CaMK II gamma in patients with CML in accelerated phase andblast crisis was high.In chronic phase patients,the expression was low or no,and the expression was consistent with beta-catenin.Conclusion CaMKII gamma played an important role in the transition period from chronic phase to acute phase,and it can affect the self-renewal of leukemia stem cell through the regulation of beta-catenin.

参考文献/References:

[1] Rowley JD.Letter:A new consistent chromosomal ab-normality inchronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining[J].Nature,1973,243(5405):290-293.
[2] Goldman JM,Melo JV.Chronic myeloid leukemia-advances in biology and new approaches to treatment[J].N Engl J Med,2003,349(15):1451-1464.
[3] Si J,Mueller L,Collins SJ.CaMKⅡ regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells[J].J Clin Invest,2007,117(5):1412-1421.
[4] Gu Y,Chen T,Meng Z,et al.CaMKⅡγ,a critical regulator of CML stem/progenitor cellsis a target of the natural product berbamine[J].Blood,2012,120(24):4829-4839.
[5] 张之南.血液病诊断及疗效标准[M].2版.北京:科学出版社,1998:168-360. Zhang ZN.Diagnosis and efficacy standard of hematological diseases[M].Second Edition.Beijing:Science Press,1998:168-360.
[6] 郝英婵.慢性髓细胞白血病TKIs耐药与氧化应激损伤关系的研究进展[J].徐州医学院学报,2016,36(8):554-556. Hao YC.Research progress of chronic myeloid leukemia TKIs resistance andoxidative stress injury[J].Journal of Xuzhou Medical College,2016,36(8):554-556.
[7] 苗玉迪,魏绪仓.达沙替尼联合氟达拉滨对慢粒K562细胞的抑制作用研究[J].现代检验医学杂志,2015,30(5):70-72,75. Miao YD,Wei XC.Study on inhibition of dasatinib and fludarabine toCML K562[J].Journal of Modern Laboratory Medicine,2015,30(5):70-72,75.
[8] Ripple MJ,Parker Struckhoff A,Trillo-tinoco J,et al.Activation of c-Myc and Cyclin D1 by JCV T-Antigen and β-catenin in colon cancer[J].PLoS One,2014,9(9):e106257.
[9] Herrmann H,Sadovnik I,Cerny-Reiterer S,et al.Dipeptidylpeptidase IV(CD26)defines leukemic stem cells(LSC)in chronic myeloid leukemia[J].Blood,2014,123(25): 3951-3962.
[10] Ng KP,Manjeri A,Lee KL,et al.Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition[J].Blood,2014,123(21):3316-3326.
[11] Hu Y,Chen Y,Douglas L,et al.β-Catenin is essential for survival ofleukemia stem cells in sensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia[J].Leukemia,2009,23(1):109-116.
[12] Zhao C,Blum J,Chen A,et al.Loss of beta-catenin impairs the renewalof normal and CML stem cells in vivo[J].Cancer Cell,2007,12(6):528-541.

相似文献/References:

[1]陈 静,鞠 镇.一代和二代酪氨酸激酶抑制剂治疗 对CML染色体的影响及疗效[J].现代检验医学杂志,2015,30(01):91.[doi:10.3969/j.issn.1671-7414.2015.01.025]
　CHEN Jing,JU Zhen.Chromosome's Influence and Curative Effect on First and Second Generation Tyrosine Kinase Inhibitor Therapy to CML[J].Journal of Modern Laboratory Medicine,2015,30(03):91.[doi:10.3969/j.issn.1671-7414.2015.01.025]
[2]刘伟平,官凡琪,宋耀辉,等.慢性粒细胞白血病患者BCR-ABL融合基因P210表达对病程判断和预后评估的临床价值[J].现代检验医学杂志,2019,34(05):12.[doi:10.3969/j.issn.1671-7414.2019.05.004]
　LIU Wei-ping,GUAN Fan-qi,SONG Yao-hui,et al.Clinical Value of BCR-ABL Fusion Gene P210 Expression of Patients with Chronic Myeloid Leukemia for Course Judgment and Prognosis Evaluation[J].Journal of Modern Laboratory Medicine,2019,34(03):12.[doi:10.3969/j.issn.1671-7414.2019.05.004]

备注/Memo

备注/Memo:
作者简介:张文静(1983-),女,主管技师,硕士,研究方向:白血病发病机制,E-mail:379667349@qq.com。 通讯作者:王保龙(1965-),男,主任技师,教授,博士生导师,研究方向:肿瘤分子生物学,E-mail:wbl1965@163.com。
更新日期/Last Update: 2018-04-16